Uciane Scarlett, Ph.D.

Dr. Uciane Scarlett is responsible for investment identification, due diligence, business development and new company creation activities at MPM BioImpact.

Prior to joining MPM BioImpact, Uciane was a Principal at Oxford Sciences Enterprise (OSI, UK), an Oxford-affiliated firm, where she initially co-led the life science sector. While at OSE, Uciane led financings and drove company creation efforts for several companies including T-Cypher Bio, where she served as interim Executive Chair, Alethiomics, PepGen and Endlyz. She represented OSE on the boards of T-Cypher, PepGen, Miro Bio, Scenic Bio, and DJS. Prior to OSE, Uciane was on the investment team at Atlas Venture where she drove company creation, operations, and financings activities for Dyne Therapeutics (DYN) and Quench Bio and served in operational roles for AVROBIO (AVRO) and KorroBio. Uciane was the Director of BD & Strategy at Compass Therapeutics prior to Atlas.

Uciane holds a Ph.D. in cancer immunology from Dartmouth College. She received her BSc, first-class honors, in biotechnology (major) and zoology (minor) from the University of the West Indies.